Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript
Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
Jazz Pharmaceuticals NASDAQ: JAZZ outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA.
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating.
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Actio's lead drug for KCNT+ epilepsy, ABS-1230.
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
JAZZ vs. TECH: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
Jazz Pharmaceuticals' Re-Rating Story Has Legs
Jazz Pharmaceuticals has delivered strong year-to-date performance, raising full-year revenue guidance. JAZZ's oxybate franchise, led by Xywav, continues double-digit growth despite the full generic Xyrem launch, driving a significant guidance increase. Ziihera's potential first-line GEA approval this month could unlock a large new revenue stream and accelerate sequential growth.
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript
Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metrics
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $6.04 per share. This compares to a loss of $8.25 per share a year ago.
